Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

Fig. 3

Validation of prognostic value of the ROS scoring system in Tothill and TJ datasets. a A Kaplan-Meier analysis of overall survival (OS) for ovarian cancer patients in Tothill (GSE9899) dataset with the ROS scoring system is shown (P = 0.022, respectively, log-rank test). b A Kaplan-Meier analysis of overall survival (OS) for ovarian cancer patients in TJ dataset with the ROS scoring system is shown (P = 0.003, respectively, log-rank test). c Univariate and multivariable Cox proportional hazards regression analyses incorporating the score and known prognostic clinical factors, including age at diagnosis (≤59 v.s. ≥60 years), stage (III v.s. IV), grade (1–2 v.s. 3), and extent of surgical debulking (0–10 v.s. ≥11 mm residual tumor); each as categorical variables. Solid squares represent the hazard ratio (HR) of death and open-ended horizontal lines represent the 95% confidence intervals (CIs). All P values were calculated using Cox proportional hazards analysis.

Back to article page